Skip to main content
    V

    Vor Biopharma Inc (VOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.88
    +1.22 (+6.54%)

    Market Cap: $1.15B

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(9/25)
    Avg Surprise
    +566.84%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-4.68
    Range$-5.03 - $-4.32
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Period ending Mar 31, 2027
    EPS Consensus$-0.94
    Range$-1.37 - $-0.74
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.85-11.2%
    60d ago$-0.85-11.2%
    30d ago$-0.940.0%
    7d ago$-0.940.0%
    Current$-0.94
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Last 12 of 31 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$-0.94$-1.37 - $-0.74--4
    0
    1
    30d
    		-
    Dec 26EST
    		-$-4.68$-5.03 - $-4.32--2--
    Sep 26
    Reported Oct 30
    		$-0.90$-0.81$-0.81 - $-0.81-11.11%Miss1
    1
    1
    30d
    		+99.3%
    Jun 26
    Reported Aug 11
    		$-0.80$-0.69$-0.82 - $-0.59-15.94%Miss2
    1
    2
    30d
    		+99.7%
    Mar 26
    Reported May 13
    		$-0.73$-0.78$-0.88 - $-0.69+6.41%Beat4
    3
    0
    30d
    		+86.0%
    Dec 25
    Reported Mar 30
    		$307.53$-1.19$-1.90 - $-0.44+25921.16%Beat6
    1
    0
    30d
    		+69993.2%
    Sep 25
    Reported Nov 13
    		$-121.63$-4.10$-4.22 - $-3.98-2866.59%Miss2
    No revisions (30d)
    		-1420.4%
    Jun 25
    Reported Aug 12
    		$-251.20$-11.80$-12.46 - $-11.41-2028.81%Miss3
    0
    1
    30d
    		-2963.4%
    Mar 25
    Reported May 14
    		$-5.20$-4.16$-4.20 - $-4.08-25.00%Miss5
    2
    1
    30d
    		+42.2%
    Dec 24
    Reported Mar 20
    		$-0.44$-0.31$-0.36 - $-0.20-43.46%Miss6
    No revisions (30d)
    		-12.8%
    Sep 24
    Reported Nov 7
    		$-8.00$-0.40$-0.44 - $-0.36-1900.00%Miss9
    No revisions (30d)
    		+18.4%
    Jun 24
    Reported Aug 8
    		$-8.20$-8.29$-8.34 - $-8.23+1.09%Beat9
    No revisions (30d)
    		+8.9%
    Mar 24
    Reported May 9
    		$-9.00$-7.63$-7.67 - $-7.59-17.96%Miss9
    No revisions (30d)
    		-4.7%
    Dec 23
    Reported Mar 20
    		$-0.39$-0.50$-0.53 - $-0.46+22.00%Beat9
    No revisions (30d)
    		+25.0%

    Key Metrics

    Valuation
    P/E Ratio0.07EV/EBITDAN/A
    Price/FCF-9.91xFCF Yield-10.09%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-125.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.50xQuick Ratio13.50x
    Trading Statistics
    Beta1.83Avg Volume799.25K
    52-Week High$26.0052-Week Low$6.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.69
    SMA 20$19.25
    SMA 50$20.36
    SMA 200$17.41
    EMA 10$19.54
    EMA 20$19.49
    EMA 50$19.85
    EMA 200$18.92

    MACD

    Line: -0.05Signal: -0.17Hist: 0.13

    ADX

    ADX: 9.7+DI: 22.3-DI: 23.5

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down64.0
    PSAR$21.67

    Bollinger Bands

    Upper Band$20.87
    Lower Band$17.63
    %B Position1683%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    51.7

    Momentum Oscillators

    Stoch %K45.9
    Stoch %D47.4
    Williams %R-46.0
    ROC (10d)8.9%
    Momentum1.62
    CCI (20d)23.7
    MFI (14d)62.3

    Volatility Measures

    ATR (14d)$1.31(6.6%)
    StdDev (20d)0.81
    Hist Vol67.1%(High)

    Volume Flow

    VWAP$19.50
    OBV812.4M
    AD Line205.4B
    CMF (20d)-0.176

    Volume Metrics

    Avg Vol (20d)753.7K
    Vol Ratio0.7x
    VWMA (20d)$19.30

    Pivot Points

    R3$21.47
    R2$20.77
    R1$19.72
    Pivot Point$19.02
    S1$17.97
    S2$17.27
    S3$16.22

    Advanced Oscillators

    TSI-1.28
    Ultimate Osc45.5
    KST-15.64

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0$0$0$0$0$0$0$3.69M$0$0$0$12.23M
    Cost of Revenue$0$0$0$23,000$0$0$0$865,000$0$0$0$892,000
    Gross Profit$0$0$0$-23,000$0$0$0$-865,000$0$0$0$-892,000
    Operating Expenses$58.44M$47.85M$35.16M$35.96M$28.11M$274.28M$33.29M$31.31M$28.51M$29.04M$32.33M$28.12M
    R&D$34.53M$25.92M$17.59M$19.19M$14.14M$261.50M$26.70M$25.35M$21.82M$21.82M$24.32M$20.90M
    SG&A$23.91M$21.93M$17.57M$16.77M$13.96M$12.79M$6.59M$5.96M$6.70M$7.21M$8.00M$7.23M
    Operating Income$-58,444,000$-47,853,000$-35,160,000$-35,960,000$-28,107,000$-274,284,000$-33,291,000$-31,311,000$-28,513,000$-29,035,000$-32,326,000$-28,124,000
    Interest Income$4.61M$4.34M$3.94M$2.79M$1.73M$537,000$805,000$599,000$954,000$1.20M$1.52M$1.86M
    Interest Expense$28.28M$14.96M$184.43M$0$784.58M$1.30B$0$0$0$0$0$0
    Income Before Tax$-86,727,000$-62,810,000$-219,585,000$1.72B$-812,684,000$-1,573,669,000$-32,486,000$-30,712,000$-27,559,000$-27,839,000$-30,804,000$-26,261,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-86,727,000$-62,810,000$-219,585,000$1.72B$-812,684,000$-1,573,669,000$-32,486,000$-30,712,000$-27,559,000$-27,839,000$-30,804,000$-26,261,000
    EBITDA$-91,760,000$-67,542,000$-223,980,000$-35,971,000$-814,424,000$-1,572,180,000$-32,477,000$-30,458,000$-27,673,000$-28,495,000$-32,180,000$-28,218,000
    EBIT$-91,334,000$-67,153,000$-223,520,000$-35,960,000$-814,415,000$-1,574,206,000$-33,291,000$-31,311,000$-28,513,000$-29,035,000$-32,326,000$-28,124,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VOR

    News

    Vor Biopharma (VOR) executive Sokolove gave up 1,917 shares at $19.25 to cover taxes or an exercise price

    Jeremy Brett Sokolove, Chief Medical Officer at Vor Biopharma Inc. (VOR), reported giving up 1,917 shares at $19.25 on November 2, 2026...

    Quantisnow•11/4/26•Neutral

    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Vor Bio announced that its Compensation Committee granted stock options and restricted stock units (RSUs) to two new employees on November 1, 2026, as material inducements for employment. These grants...

    GlobeNewswire•11/4/26•Neutral

    Weekly Recap: Phase 3 enrollment complete and Q3 net loss falls

    Vor Biopharma (NASDAQ:VOR) has completed enrollment for its Phase 3 UPSTREAM MG trial, with results anticipated in the first half of 2027. The company reported a Q3 net loss of $86.7 million and has $481.6 million...

    TradingView•11/2/26•Neutral

    Vor Biopharma (VOR) Reiterated at Buy by Stifel After Earnings, Corporate Update

    Stifel analyst Stephen Willey reiterated a Buy rating and a $40.00 price target for Vor Biopharma (NASDAQ: VOR) following the company's earnings and corporate update. The article mentions this as premium content...

    StreetInsider•11/2/26•Bullish

    VOR: MG trial enrollment is complete; $481.6M cash supports a projected runway into early 2029

    Vor Biopharma Inc. (VOR) has announced the completion of enrollment for its MG trial, with topline results anticipated in the first half of 2027. The company's cash reserves of $481.6 million are expected to fund...

    TradingView•10/31/26•Bullish

    VOR Valuation and Fair Value

    P/E
    0.1x
    P/FCF
    -9.9x
    P/B
    -8.6x
    See GNG's fair value

    VOR Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -125.4%
    FCF yield
    -10.1%

    VOR Competitors

    CompanyTicker
    Omada Health, Inc. Common StockOMDA
    Verastem IncVSTM
    CareCloud, Inc.CCLDO
    Iradimed CoIRMD
    Inhibrx Biosciences, Inc.INBX
    Integra LifeSciences HoldingsIART
    Goodrx Holdings IncGDRX
    Si-Bone IncSIBN

    Sector: Healthcare

    VOR Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    1
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VOR Bull Case vs Bear Case

    Bull case

    • 88.9% of VOR's analyst ratings are Buy or Strong Buy.

    Bear case

    • VOR beat EPS estimates in 25.0% of its last 8 reported quarters.

    VOR Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -712.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-4.68

    VOR Earnings Date

    VOR reports Mar 29, 2027, after the close. The date is estimated.

    VOR ETF Holders

    GNG tracks 8 ETFs that hold VOR. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.22% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.06% of the fund
    3. BlackRock Health Sciences Trust (BME), 0.03% of the fund
    4. Vanguard Health Care Index Fund ETF Shares (VHT), 0.01% of the fund
    5. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for VOR

    See insider activity

    Frequently Asked Questions About VOR

    When does VOR report earnings?

    Vor Biopharma Inc (VOR) is expected to report earnings on Mar 29, 2027.

    Does VOR pay dividends?

    Vor Biopharma Inc (VOR) does not currently pay a regular dividend.

    What is VOR's P/E ratio?

    Vor Biopharma Inc has a price-to-earnings (P/E) ratio of 0.07.

    What is VOR's market cap?

    Vor Biopharma Inc (VOR) has a market capitalization of $1.15B with a current stock price of $19.88.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In